EBV is a B-lymphotrophic g1-herpesvirus with potent in vitro growth-transforming properties. In vivo, its oncogenic potential is exemplified by post transplant lymphoproliferative disease (PTLD) arising in T cell compromised hosts. Following allo-SCT, PTLD is invariably EBV-driven and of B-cell origin. Although EBV genomes can be detected in biopsy tissue of peripheral T-cell lymphoma (PTCL), EBV-harbouring cells are typically microenvironmental B-lymphocytes; the malignant T cells are EBV-negative. 1 Indeed, with the exception of distinct entities such as extra-nodal T/ natural killer (NK) lymphomas, EBV þ T-cell lymphomas are rare. 2 Moreover, although the mechanism of virus entry into B cells is well characterized, facilitated by viral engagement with surface CD21 and HLA class II, it remains unclear how the virus enters T or NK cells. 3 We describe a patient with a primary diagnosis of EBV-negative PTCL (not otherwise specified (NOS)) presenting following alloSCT with a systemic illness associated with high EBV genome numbers in peripheral blood. Unexpectedly, the diagnosis was not EBVassociated B-cell PTLD but T-cell lymphoma, phenotypically identical to the primary PTCL lesion, but now EBV positive.
A 53-year-old man presented with weight loss and lymphadenopathy. Lymph node tissue was effaced by large lymphoid blasts expressing T-cell markers, including CD2, CD3, CD4, CD5 and CD7, and patchy CD30 expression. CD8, CD56, ALK and EBER (by in situ hybridization) were all negative. Aberrant expression of CD79a was noted (Figure 1) . A diagnosis of PTCL-NOS was assigned and corroborated by national reference laboratory expert review. Initial treatment with CHOP chemotherapy was unsuccessful and the disease remained refractory to two lines of salvage chemotherapy (IVE: Ifosphamide/Epirubicin/Etoposide, and GemP: Gemcitabine/Methylprednisolone/Cisplatin). However, complete metabolic response (Positron emission tomography-computerized tomography (PET-CT)_ criteria) was attained following two cycles of FLUDAP (Fludarabine/Dexamethasone/Cytosine arabinoside/ Cisplatin). 4 In view of the high relapse risk and the availability of a 10/10 HLA-matched unrelated donor (MUD), he proceeded to alloSCT with reduced-intensity conditioning (Fludarabine/ Melphalan with Alemtuzumab as in vivo T-cell depletion). CsA was given as GVHD prophylaxis and weaned from D þ 50. The initial post transplant course was unremarkable with prompt engraftment, achievement of full-donor chimerism and no acute GVHD. Routine surveillance for EBV reactivation was undertaken by weekly quantitative PCR (qPCR) on blood. Consecutive samples until D þ 76 showed no evidence of EBV reactivation.
One week later, a progressive fall in Hb, derangement of liver enzymes and hyperbilirubinaemia were noted. Acute liver GVHD was suspected and 1 mg/kg of prednisolone was started. EBV copy number rose slightly to 510 copies/mL, and therefore pre-emptive intervention with Rituximab 375 mg/m 2 was initiated. No improvement was seen; liver enzymes escalated and the anaemia worsened, requiring transfusion. Ultrasound examination showed no abnormality of the liver, but new splenomegaly was noted. Liver biopsy showed nonspecific inflammatory change. Despite two doses of Rituximab, EBV qPCR values rose rapidly, reaching 7.5 Â 10 4 copies/mL within 2 weeks. PET-CT revealed intense 18 Fluorodeoxyglucose-uptake in lymph nodes above and below the diaphragm, the spleen as well as foci of skeletal uptake (Figure 2a ). An EBV-associated (rituximab refractory) B-cell PTLD was considered the most likely diagnosis. Progressive pancytopenia then prompted a BM biopsy demonstrating large lymphoid blasts, negative for CD20 but expressing CD79a (Figure 2b ). As anticipated, these cells expressed EBV-encoded small RNA (EBERs). The absence of CD20 on the EBER-expressing cells was initially attributed to the Rituximab therapy. However, urgent review of the diagnostic PTCL-NOS lymph node reiterated that the original T-cell malignant clone aberrantly co-expressed the B-cell antigen CD79a (Figure 1 ). Consequently, a T-cell panel was applied to the 'PTLD' BM biopsy and revealed that the CD79a þ /EBER þ cells were actually T cells expressing CD2, CD3, CD4, CD5 and CD7. This was an identical phenotype to the original PTCL-NOS clone but with development of EBER co-expression (Figure 2b) . The viral receptor, CD21, was not expressed on the malignant T cells (data not shown).
In view of these findings, Rituximab therapy was discontinued and immunosuppression with Cyclosporin rapidly withdrawn in an attempt to improve donor effector T-cell function. Given the refractoriness of the PTCL-NOS to chemotherapy, unselected donor lymphocytes (5 Â 10 5 CD3 þ ve cells/kg) from the EBVimmune stem cell donor were administered. Despite this, rapid clinical deterioration ensued with progressive disease, coagulopathy and multi-organ failure; the patient subsequently died on day þ 117 following alloSCT.
EBV is markedly B lymphotropic both in vitro and in vivo. EBV is not detected in NK or T cells in the blood of healthy carriers, but has been reported at extremely low frequencies in tonsillar NK or T cells. 5 Such events are considered very rare, consistent with the absence of the major viral receptor, CD21, on mature T and NK cells. Nonetheless, following initial clinico-pathological descriptions, 6-8 a distinct spectrum of EBV-associated lymphoproliferations of T and NK origin were characterized. 3 Importantly, malignant T cells in (WHO-defined 2 ) PTCL-NOS biopsies are EBV-negative and no clear role for EBV in the pathogenesis of PTCL-NOS has been forthcoming. 9 We present a patient in whom the onset of an EBV-associated illness following a T-cell-depleted MUD alloSCT was consistent with a diagnosis of PTLD. However, aberrant expression of the B-cell antigen CD79a on the PTCL-NOS clone was deceptive; review of the original lymph node tissue permitted a diagnosis of EBV-associated relapse of PTCL-NOS. A single report has described secondary EBV infection of a CD8 þ malignancy, 10 but we are not aware of a previous description of such a phenomenon in this context. Our case illustrates that EBV is capable of infecting malignant T cells in vivo, in a state of ostensibly minimal residual disease and in the face of impaired host effector T-cell function. Given that EBV infection of T cells is a rare event, but the vast majority of PTCL-NOS cells in the BM biopsy in our case expressed EBERs, it follows that viral entry into a single or small number of residual cells led to the expansion of the EBV-infected T-cell clone. The absence of CD21 expression on the malignant T cells indicates that an alternate mechanism of viral entry into T cells was employed. This unusual clinico-pathological observation opens up further questions relating to the complex relationship of this oncogenic herpesvirus with malignancies of T and NK cell origin.
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